following an abbreviated submission:
upadacitinib (Rinvoq®) is accepted for restricted use within NHSScotland.
Indication under review: for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate.
SMC restriction: for use in patients with psoriatic arthritis whose disease has not responded adequately to at least two conventional DMARDs (cDMARDs), given either alone or in combination.
Upadacitinib offers an additional treatment choice in the therapeutic class of Janus Kinase (JAK) inhibitors in this setting.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice631KB (PDF)
Medicine details
- Medicine name:
- upadacitinib (Rinvoq)
- SMC ID:
- SMC2361
- Indication:
For the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Upadacitinib may be used as monotherapy or in combination with methotrexate
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 10 May 2021